Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer

被引：0
|
作者：
Kentaro Sudo
Takeshi Ishihara
Nobuto Hirata
Fumiaki Ozawa
Tadashi Ohshima
Ryosaku Azemoto
Kenji Shimura
Takeshi Nihei
Takayoshi Nishino
Akihiko Nakagawa
Kazuyoshi Nakamura
Taro Hara
Motohisa Tada
Rintaro Mikata
Katsunobu Tawada
Osamu Yokosuka
So Nakaji
Taketo Yamaguchi
机构：
[1] Chiba Cancer Center,Department of Gastroenterology
[2] Chiba University,Department of Gastroenterology and Nephrology, Graduate School of Medicine
[3] Kameda Medical Center,Department of Gastroenterology
[4] Saitama Medical University,Department of Hepato
[5] Saitama Red Cross Hospital,biliary
[6] Kimitsu Chuo Hospital,pancreatic Surgery, Saitama Medical Center
[7] Asahi General Hospital,Department of Gastroenterology
[8] Mito Saiseikai General Hospital,Department of Gastroenterology
[9] Tokyo Women’s Medical University Yachiyo Medical Center,Department of Gastroenterology
[10] Numazu City Hospital,Department of Internal Medicine
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 73卷
关键词：
Pancreatic cancer; S-1; Gemcitabine; Randomized controlled study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：389 / 396
页数：7
相关论文
共 50 条
  • [1] Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer
    Sudo, Kentaro
    Ishihara, Takeshi
    Hirata, Nobuto
    Ozawa, Fumiaki
    Ohshima, Tadashi
    Azemoto, Ryosaku
    Shimura, Kenji
    Nihei, Takeshi
    Nishino, Takayoshi
    Nakagawa, Akihiko
    Nakamura, Kazuyoshi
    Hara, Taro
    Tada, Motohisa
    Mikata, Rintaro
    Tawada, Katsunobu
    Yokosuka, Osamu
    Nakaji, So
    Yamaguchi, Taketo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (02) : 389 - 396
  • [2] A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer.
    Omuro, Y.
    Ikari, T.
    Ishii, H.
    Ozaka, M.
    Suyama, M.
    Matsumura, Y.
    Itoi, T.
    Egawa, N.
    Yano, S.
    Hanada, K.
    Kimura, Y.
    Ukita, T.
    Ishida, Y.
    Tani, M.
    Ohoka, S.
    Hirose, Y.
    Hijioka, S.
    Watanabe, R.
    Ikeda, T.
    Nakajima, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Retrospective Study of Gemcitabine plus S-1 versus Gemcitabine Alone in Cases with Unresectable Advanced Pancreatic Cancer
    Suzuki, Shuji
    Ozaki, Yuhi
    Saida, Shin
    Kaji, Satoshi
    Koike, Nobusada
    Harada, Nobuhiko
    Hayashi, Tsuneo
    Suzuki, Mamoru
    HEPATO-GASTROENTEROLOGY, 2013, 60 (124) : 916 - 920
  • [4] Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study
    Ioka, T.
    Ikeda, M.
    Ohkawa, S.
    Yanagimoto, H.
    Fukutomi, A.
    Sugimori, K.
    Baba, H.
    Yamao, K.
    Shimamura, T.
    Chen, J.
    Mizumoto, K.
    Furuse, J.
    Funakoshi, A.
    Hatori, T.
    Yamaguchi, T.
    Egawa, S.
    Sato, A.
    Ohashi, Y.
    Cheng, A.
    Okusaka, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
    Do-Youn Oh
    Yongjun Cha
    In-Sil Choi
    So-Young Yoon
    In Keun Choi
    Jee Hyun Kim
    Sang Cheul Oh
    Chang Duck Kim
    Jae Sun Kim
    Yung-Jue Bang
    Yeul Hong Kim
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 527 - 536
  • [6] A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer
    Oh, Do-Youn
    Cha, Yongjun
    Choi, In-Sil
    Yoon, So-Young
    Choi, In Keun
    Kim, Jee Hyun
    Oh, Sang Cheul
    Kim, Chang Duck
    Kim, Jae Sun
    Bang, Yung-Jue
    Kim, Yeul Hong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (03) : 527 - 536
  • [7] Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan
    Fukutomi, Akira
    Okusaka, Takuji
    Sugimori, Kazuya
    Ueno, Hideki
    Ioka, Tatsuya
    Ohkawa, Shinichi
    Boku, Narikazu
    Yamao, Kenji
    Mizumoto, Kazuhiro
    Furuse, Junji
    Funakoshi, Akihiro
    Hatori, Takashi
    Yamaguchi, Taketo
    Egawa, Shinichi
    Sato, Atsushi
    Ohashi, Yasuo
    Cheng, Ann-Lii
    Tanaka, Masao
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer
    Ke, Qing-Hua
    Zhou, Shi-Qiong
    Yang, Ji-Yuan
    Du, Wei
    Liang, Gai
    Lei, Yong
    Luo, Fei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (38) : 13987 - 13992
  • [9] S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer
    Qing-Hua Ke
    Shi-Qiong Zhou
    Ji-Yuan Yang
    Wei Du
    Gai Liang
    Yong Lei
    Fei Luo
    World Journal of Gastroenterology, 2014, (38) : 13987 - 13992
  • [10] Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.
    Ueno, Makoto
    Ohkawa, Shinichi
    Kobayashi, Noritoshi
    Sugimori, Kazuya
    Kawaguchi, Yoshiaki
    Kobayashi, Satoshi
    Taguri, Masataka
    Yamanaka, Takeharu
    Mine, Tetsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345